Compare
Creative Medical Technology Holdings, Inc. vs Entera Bio Ltd. vs VivoSim Labs, Inc. vs Zivo Bioscience, Inc.
| Latest fiscal year | Creative Medical Technology Holdings, Inc. CELZ | Entera Bio Ltd. ENTX | VivoSim Labs, Inc. VIVS | Zivo Bioscience, Inc. ZIVOLast annual report: year ended 2024-12-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2024-12-31 |
| Revenue | $6.0K | $42.0K | $131.0K | $157.2K |
| Revenue growth (YoY) | -45.5% | -76.8% | -9.0% | +468.6% |
| Gross margin | 63.4% | 0.0% | n/a | 31.1% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$6.00M | -$11.44M | -$13.84M | -$13.38M |
| EPS (Diluted) | -$2.52 | $0.25 | -$5.35 | -$4.23 |
| Operating cash flow | -$5.86M | -$7.37M | -$10.83M | -$4.31M |
| Free cash flow | n/a | -$7.48M | -$10.83M | n/a |
| Cash & equivalents | n/a | $7.11M | $5.02M | n/a |
| Total assets | $7.81M | $15.99M | $7.39M | $1.64M |
| Total liabilities | $284.9K | $2.89M | $8.48M | $2.16M |
| Shareholders' equity | $7.51M | $13.10M | -$1.10M | -$514.9K |
| Return on year-end equity | -79.8% | -87.3% | n/a | n/a |
| Shares outstanding | 3.70M | 46.18M | 2.89M | 3.62M |
Revenue, most recent five fiscal years
| Fiscal year | Creative Medical Technology Holdings, Inc. | Entera Bio Ltd. | VivoSim Labs, Inc. | Zivo Bioscience, Inc. |
|---|---|---|---|---|
| Latest | $6.0K Ended 2025-12-31 | $42.0K Ended 2025-12-31 | $131.0K Ended 2026-03-31 | $157.2K Ended 2024-12-31 |
| 1 year earlier | $11.0K Ended 2024-12-31 | $181.0K Ended 2024-12-31 | $144.0K Ended 2025-03-31 | $27.6K Ended 2023-12-31 |
| 2 years earlier | $9.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $109.0K Ended 2024-03-31 | $0 Ended 2022-12-31 |
| 3 years earlier | $88.6K Ended 2022-12-31 | $134.0K Ended 2022-12-31 | $370.0K Ended 2023-03-31 | $0 Ended 2021-12-31 |
| 4 years earlier | $87.8K Ended 2021-12-31 | $571.0K Ended 2021-12-31 | $1.50M Ended 2022-03-31 | $20.0K Ended 2020-12-31 |